Generic Drug Product Development: Process and Evidence

How Does the Generic Drug Development Process Work?

The generic drug development process is best managed as connected workstreams rather than a rigid sequence. Findings in formulation, analytical development, stability, process scale-up or equivalence planning can require earlier assumptions to be reconsidered.

Swipe horizontally to view all table columns.

The precise sequence and evidence requirements vary by product, dosage form, regulatory pathway and market. This is a programme-planning framework, not a universal filing checklist.

Where Does a Generic Development Programme Begin?

Generic development begins by defining the product that the proposed medicine is expected to reference or compare against, and by confirming the intended market pathway. That decision informs formulation objectives, analytical comparisons, bioequivalence planning, labelling, packaging and dossier requirements.

The reference product is not simply a sample whose composition is reproduced. It is the benchmark against which relevant pharmaceutical and performance characteristics are assessed. The team should establish the active ingredient, strength, dosage form, route of administration, release characteristics, approved use and market-specific regulatory status before experimental development begins.

Comparator procurement and characterisation should follow a documented plan. Where relevant, multiple lots may be examined so normal product variability is not mistaken for one fixed target. Source market, batch number, expiry, storage history and packaging configuration should remain traceable. Patent, exclusivity and freedom-to-operate questions require appropriately qualified legal advice; pharmaceutical development data do not constitute a legal opinion.

Swipe horizontally to view all table columns.

Defining the Quality Target Product Profile

A generic product development programme converts market requirements, reference-product knowledge and patient-use considerations into a prospective Quality Target Product Profile.

A Quality Target Product Profile (QTPP) describes the quality characteristics the product should possess to deliver its intended performance. Depending on the dosage form and pathway, it may address strength, route, release behaviour, stability, container-closure system and other quality-related requirements. Potential Critical Quality Attributes (CQAs) are then identified by considering which physical, chemical, biological or microbiological attributes must remain within appropriate limits to assure product quality.

The QTPP and CQAs are not static checklists. They guide the investigation of material attributes, formulation variables and process parameters, and they should be reassessed as product knowledge develops. This risk-based approach is consistent with the pharmaceutical-development principles described in ICH Q8(R2).

Preformulation should identify practical development risks, not merely produce descriptive data. It helps the team assess whether particle-size control may be needed, whether direct compression is feasible, whether moisture-sensitive processing should be avoided, which excipient functions are required and which analytical tools must be in place before formulation screening begins.

How Do Formulation and Analytical Development Progress Together?

Formulation and analytical development are interdependent workstreams. Formulation experiments cannot be interpreted reliably without suitable analytical methods, and analytical procedures should be capable of detecting meaningful differences caused by materials, processing, storage and product ageing.

Early methods may be fit for screening rather than final release testing, so their purpose and maturity should be clearly defined. As the formulation and process become more stable, analytical procedures, specifications and validation evidence should mature accordingly. ICH Q14 describes science- and risk-based analytical procedure development, while ICH Q2(R2) addresses validation principles. The applicable expectations continue to depend on the product, method and intended market.

The same integrated logic applies to pharmaceutical analytical R&D: methods, dissolution work and stability data must help the team select and defend a formulation rather than simply test a finished sample.

Swipe horizontally to view all table columns.

What Changes for Solid Oral Dosage Forms?

Generic drug product development for solid oral dosage forms requires particular attention to material behaviour, process selection, disintegration, dissolution, stability and the equivalence strategy. Immediate-release and modified-release products should not be treated as interchangeable development problems because their performance mechanisms and regulatory expectations can differ materially.

For tablets and capsules, relevant factors can include API dose, solubility, permeability, particle and solid-state properties, excipient functionality and intended release profile. An appropriate generic development strategy evaluates those factors in relation to the target product, rather than applying a standard formula or processing route.

Dissolution testing should provide development-relevant information. A method used only because it produces rapid release may not distinguish changes in API, formulation or process that affect product behaviour. Media, agitation, sampling points and acceptance criteria should be selected with reference to the dosage form, API properties, compendial information and current authority guidance.

How Does the Process Move from Laboratory to Commercial Scale?

A successful laboratory formulation is not automatically a scalable product. Equipment geometry, mixing intensity, granulation end point, drying behaviour, milling, lubrication, material transfer, compression dwell time and coating conditions can change as batch size and equipment change.

Scale-up assesses whether the product and process remain capable of meeting defined CQAs under representative operating conditions. Critical material attributes and critical process parameters should be connected to observed product performance. Unexpected results, deviations and edge-of-range experiments can provide useful product understanding when they are investigated and documented rather than excluded from the development history.

1. Confirm material controls. Raw-material specifications and supplier controls should support the intended process and the evaluated formulation.
2. Translate laboratory operations. Convert laboratory activities into defined manufacturing instructions, in-process controls and a traceable batch record approach.
3. Assess scale-relevant variables. Evaluate equipment and batch-size effects against the CQAs and intended product performance.
4. Use representative evidence. Generate stability and equivalence evidence at the batch stage required by the applicable pathway.
5. Transfer the rationale. Carry formulation, process, analytical methods, specifications, packaging requirements and product knowledge through controlled documentation.

A technology-transfer package should explain not only what is to be performed, but why identified controls matter. Formula, manufacturing sequence, hold times, sampling, analytical methods, in-process limits, packaging, storage and deviation-management responsibilities should remain consistent across development, quality and receiving-site teams.

How Do Stability, Dossier and Lifecycle Planning Connect?

Stability and dossier planning run through the development programme; they are not tasks reserved for the final submission stage. A change in formulation, process, packaging or batch scale can affect stability relevance, analytical comparability, equivalence planning and the consistency of the eventual dossier.

Stability protocols should be aligned with the product, packaging, storage proposal and target market. The data need to remain traceable to the batches, methods, specifications and manufacturing conditions described elsewhere in the quality package. This is especially important when a development batch, a pivotal comparative batch and the proposed commercial process do not align closely.

When preparing a dossier, teams should maintain a clear link between raw data, development reports, analytical methods, stability summaries, batch records and the scientific rationale in the relevant section of the application. The Common Technical Document gives a shared structure across ICH regions, but regional administrative content and technical requirements remain market-specific. ICH CTD overview

What Evidence Supports Pharmaceutical Equivalence and Bioequivalence?

Generic product development needs a defined relationship between the proposed product and an appropriate comparator. Depending on the jurisdiction, the evidence package may need to show the required relationship in active ingredient, strength, dosage form, route, quality, performance and intended use. Pharmaceutical equivalence alone does not establish that products will perform similarly in vivo.

The evidence should be developed as an integrated body of product and process knowledge. ICH Q8(R2) describes pharmaceutical development in terms of the drug substance, excipients, formulation, manufacturing process, container-closure system, CQAs and control strategy. The WHO guidance on multisource pharmaceutical products similarly focuses on designing a quality product and manufacturing process capable of consistently delivering the intended performance.

Swipe horizontally to view all table columns.

For immediate-release solid oral dosage forms within its scope, ICH M13A provides harmonised recommendations on pharmacokinetic bioequivalence study design and data analysis. It should not be extended without qualification to products outside its scope, including cases that may need separate guidance for narrow therapeutic index drugs, highly variable drugs or complex study designs.

An in-vivo study is not automatically required in every case. A WHO BCS-based biowaiver guideline allows a biowaiver to be considered when the product and supporting evidence meet the applicable eligibility criteria. A biowaiver is a justified strategy that must be accepted by the receiving authority, not an assumed exemption.

How Do Regulatory Expectations Differ Across Markets?

The scientific principles behind generic development are broadly shared, but comparator selection, submission routes, study requirements and authority interactions remain market-specific. A programme intended for several markets should therefore define the regulatory strategy before pivotal batches or bioequivalence protocols are finalised.

In the United States, a generic product is submitted through an Abbreviated New Drug Application (ANDA). A review of the current FDA Product-Specific Guidances confirms that the recommended evidence may differ according to active ingredient, dosage form, route and product complexity. An ANDA and its terminology should not be assumed to apply unchanged outside the United States.

For broader international planning, the WHO interchangeability guideline provides a scientific framework for considering in-vivo and in-vitro evidence. WHO and ICH guidance can inform a harmonised technical approach, but neither replaces the legal, procedural or comparator requirements of the national authority responsible for the application.

What Should Teams Consider for Generic Drug Development in India?

India should not be described as having a direct equivalent of the US ANDA pathway. The product’s legal and regulatory status, proposed market, comparator, evidence strategy and relevant central or state authority responsibilities should be established at the beginning of the programme.

A Government of India explanation notes that the Drugs and Cosmetics Act and Rules do not contain a standalone definition of “generic medicines”. Manufacture, sale and distribution are primarily regulated through licensing and inspection by State Licensing Authorities, while the Central Drugs Standard Control Organisation (CDSCO) has central responsibilities including new-drug and relevant bioavailability/bioequivalence oversight. Government of India clarification on generic medicines

• Product and pathway status: establish whether the product falls within relevant new-drug provisions and which application or licensing route applies before fixing the programme.
• BA/BE planning: relevant studies must follow the applicable New Drugs and Clinical Trials Rules, 2019, current amendments, ethics requirements and study-centre requirements.
• Oral dosage forms: G.S.R. 327(E) requires bioequivalence results with manufacturing-licence applications for specified oral dosage forms of BCS Class II and Class IV drugs. It should not be generalised to every generic oral product.
• Manufacturing quality: the revised Schedule M requires a pharmaceutical quality system incorporating Good Manufacturing Practices and quality risk management. It supports manufacturing quality but does not, by itself, demonstrate bioequivalence.

For an India-focused programme, current requirements should be verified against the specific product, dosage form, approval status and intended activity. Global technical guidance can support the scientific rationale, but it should not be described as a CDSCO requirement without an India-specific source. Teams seeking pathway support across India and export markets can also review Molkem’s regulatory services for India and global markets.

What Determines the Generic Drug Development Timeline?

There is no single generic drug development timeline that applies to every product. Total duration depends on the pathway, dosage-form complexity, comparator access, API readiness, analytical work, stability requirements, scale-up, equivalence strategy, manufacturing-site readiness and authority questions.

The product-development programme and the authority’s application-review period are different clocks. A published regulatory processing target should not be presented as the total time needed to develop, submit and obtain approval for a generic product. Activities can progress in parallel, but only where the teams work from a shared product definition, evidence plan and change-control process.

Swipe horizontally to view all table columns.

A pharmaceutical generic product development process should therefore measure progress through evidence readiness rather than elapsed time alone. At each milestone, the relevant question is whether formulation, analytical, stability, process and regulatory evidence is sufficient to support the next commitment without avoidable downstream rework.

Where Do Programmes Commonly Lose Time or Evidence Continuity?

The development of generic drugs is often delayed by a break between an early decision and the evidence it affects later. A disciplined programme records assumptions, reassesses them when data change and traces the impact through product, process and dossier decisions.

Generic Drug Product Development FAQs